Decatur Capital Management’s Quest Diagnostics DGX Stock Holding History

Decatur Capital Management’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-31,537	Closed	-$2.24M	–	94
2015 Q4	$2.24M	Buy	31,537 +62	+0.2%	+$4.17K	0.29%	71
2015 Q3	$1.93M	Sell	31,475 -5,250	-14%	-$367K	0.26%	70
2015 Q2	$2.66M	Sell	36,725 -20,900	-36%	-$1.54M	0.33%	66
2015 Q1	$4.43M	Hold	57,625	–	–	0.55%	46
2014 Q4	$3.86M	Sell	57,625 -14,175	-20%	-$894K	0.52%	44
2014 Q3	$4.36M	Buy	71,800 +7,975	+12%	+$491K	0.73%	45
2014 Q2	$3.75M	Hold	63,825	–	–	0.71%	59
2014 Q1	$3.7M	Buy	63,825 +21,000	+49%	+$1.13M	0.7%	59
2013 Q4	$2.29M	Sell	42,825 -53,025	-55%	-$3.14M	0.44%	76
2013 Q3	$5.92M	Buy	95,850 +61,300	+177%	+$3.67M	1.25%	37
2013 Q2	$2.1M	Buy	+34,550	New	+$2.06M	0.73%	54

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

DSA

Davis Selected Advisers Tucson, Arizona $23.3B AUM 26.95% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Decatur Capital Management's DGX Position: Q1 2016 in Review

Decatur Capital Management sold out of Quest Diagnostics (DGX) in Q1 2016, closing a stake of 31,537 shares — an estimated $2.24M sold.

Decatur Capital Management first reported a position in DGX in Q2 2013 and held it in 11 quarters. The position peaked at $5.92M in Q3 2013. 557 funds tracked by Wall St. Rank hold DGX as of Q1 2016.

Decatur Capital Management reported no remaining Quest Diagnostics position as of Q1 2016 after selling out during the quarter.
Decatur Capital Management sold 31,537 Quest Diagnostics shares in Q1 2016, an estimated $2.24M.
Decatur Capital Management first reported a position in Quest Diagnostics in Q2 2013 and held it in 11 quarters.
Decatur Capital Management's Quest Diagnostics position peaked at $5.92M in Q3 2013.
557 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2016.

Based on Decatur Capital Management's 13F filing for Q1 2016, filed 29 Apr 2016.